Oppenheimer Reiterates Buy Rating on Odyssey Therapeutics
Oppenheimer maintains its buy stance on Odyssey Therapeutics with a $40 target.
Key Points
- Oppenheimer reiterated its buy rating on Odyssey Therapeutics with a $40 price target on June 18, 2026.
- Odyssey Therapeutics trades on the NasdaqCM at around $18.36, with a market cap of approximately $899.6 million.
- The company's forward P/E ratio isn't meaningful due to negative earnings; analysts maintain a strong buy consensus.
Oppenheimer has reiterated its buy rating for Odyssey Therapeutics, Inc. (NasdaqCM: ODTX) as of June 18, 2026. The firm set a price target of $40, indicating confidence in the company's future prospects.
Analysts Set New Price Targets
On June 18, 2026, Oppenheimer reiterated its buy rating on Odyssey Therapeutics with a price target of $40. Earlier in the month, both Wedbush and JP Morgan initiated coverage on the stock with buy ratings and set price targets at $30 and $26, respectively. This suggests a positive outlook among analysts, with a consensus recommendation of strong buy and a target mean price of $32 based on three analyst opinions.
Odyssey Therapeutics Stock Snapshot
Shares of Odyssey Therapeutics are trading around $18.36 on the Nasdaq Capital Market. The company has a market cap of about $899.6 million. Despite the negative earnings per share of -$5.39, which makes the forward P/E ratio not meaningful, the stock is still considered a strong buy by analysts. The stock's 52-week range is between $15.35 and $20.30, with a 50-day and 200-day moving average both around $17.31. The company maintains a healthy current ratio of 7.20 and a quick ratio of 6.85, with a debt-to-equity ratio of 15.24.
Recent Earnings
Odyssey Therapeutics reported revenue of $2.976 million, though it did not generate a net margin, reflecting its status as a clinical-stage company. The return on equity stands at -85.5%, highlighting challenges typical for firms in the biotechnology sector. The next earnings report is anticipated on August 7, 2026.
About Odyssey Therapeutics
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The company focuses on developing innovative medicines for autoimmune and inflammatory diseases. Its pipeline includes several promising candidates, such as OD-001 for ulcerative colitis and OD-002 targeting inflammatory responses. Led by CEO Dr. Gary D. Glick, Odyssey employs around 100 people.
Bottom Line
Oppenheimer's reiterated buy rating on Odyssey Therapeutics reflects continued optimism about the company's potential in the biotechnology industry. Despite its current lack of profitability, the stock is viewed positively by analysts, with several firms initiating coverage with buy ratings. As a clinical-stage company, investors will be keenly watching future developments and clinical trial results.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.